Spectral Medical (TSE:EDT) Issues Earnings Results

Spectral Medical (TSE:EDT) announced its quarterly earnings results on Friday. The company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of C$0.28 million for the quarter.

Spectral Medical Stock Down 2.0%

Shares of EDT stock traded down C$0.02 during midday trading on Friday, reaching C$0.97. 5,110 shares of the stock were exchanged, compared to its average volume of 52,880. Spectral Medical has a 1 year low of C$0.86 and a 1 year high of C$1.54. The company’s 50 day moving average is C$1.13 and its two-hundred day moving average is C$1.30. The company has a current ratio of 0.61, a quick ratio of 0.45 and a debt-to-equity ratio of 26.03. The firm has a market cap of C$284.75 million, a PE ratio of -8.08 and a beta of 0.86.

About Spectral Medical

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.